Predictions
Molecular Templates Inc.
Start price
Target price
Perf. (%)
€3.32
12.12.21
12.12.21
-
12.12.22
12.12.22
2.65%
25.12.21
25.12.21
Could be very worthwhile Investment >20% year
Fate Therapeutics Inc.
Start price
Target price
Perf. (%)
€45.60
12.12.21
12.12.21
-
12.12.22
12.12.22
23.60%
25.12.21
25.12.21
Could be very worthwhile Investment >20% year
Adaptimmune Therapeutics PLC ADR
Start price
Target price
Perf. (%)
€3.26
12.12.21
12.12.21
-
12.12.22
12.12.22
9.82%
25.12.21
25.12.21
Could be very worthwhile Investment >20% year
Valneva SE
Start price
Target price
Perf. (%)
€23.36
12.12.21
12.12.21
-
12.12.22
12.12.22
8.73%
25.12.21
25.12.21
Could be very worthwhile Investment >20% year
Novavax Inc.
Start price
Target price
Perf. (%)
€151.40
12.12.21
12.12.21
-
12.12.22
12.12.22
5.67%
25.12.21
25.12.21
Could be very worthwhile Investment >20% year
Clovis Oncology Inc.
Start price
Target price
Perf. (%)
€2.49
12.12.21
12.12.21
-
12.12.22
12.12.22
4.74%
25.12.21
25.12.21
Could be worthwhile Investment >10% per year
Puma Biotechnology Inc.
Start price
Target price
Perf. (%)
€2.48
12.12.21
12.12.21
-
12.12.22
12.12.22
25.48%
25.12.21
25.12.21
Could be worthwhile Investment >10% per year
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€4.66
12.12.21
12.12.21
-
12.12.22
12.12.22
-1.27%
25.12.21
25.12.21
Could be worthwhile Investment >10% per year
Valneva SE
Start price
Target price
Perf. (%)
€23.36
11.12.21
11.12.21
€30.00
11.12.22
11.12.22
8.73%
25.12.21
25.12.21
Fair valuation
Very Future proof/growth oriented business model
Could be very worthwhile Investment >20% year
Higher risks for its business
Epizyme Inc.
Start price
Target price
Perf. (%)
€2.63
11.12.21
11.12.21
-
11.12.22
11.12.22
-45.63%
08.12.22
08.12.22
Probably not worthwhile Investment
Karyopharm Therapeutics Inc.
Start price
Target price
Perf. (%)
€5.24
11.12.21
11.12.21
-
11.12.22
11.12.22
-16.73%
08.12.22
08.12.22
Risky Investment
Senseonics Holdings Inc
Start price
Target price
Perf. (%)
€2.55
10.12.21
10.12.21
€10.00
31.12.23
31.12.23
-63.92%
11.06.22
11.06.22
EBIT growth > 30% per year expected
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
High Investments for future growth
Radius Health Inc.
Start price
Target price
Perf. (%)
€7.05
08.12.21
08.12.21
-
08.12.22
08.12.22
-4.99%
12.12.21
12.12.21
Risky Investment
Oncodesign S.A.
Start price
Target price
Perf. (%)
€8.61
08.12.21
08.12.21
€10.00
08.12.22
08.12.22
65.85%
09.12.22
09.12.22
Could be worthwhile Investment >10% per year
Aldeyra Therapeutics Inc.
Start price
Target price
Perf. (%)
€5.90
07.12.21
07.12.21
-
07.12.22
07.12.22
4.24%
11.12.21
11.12.21
Risky Investment
Biofrontera AG
Start price
Target price
Perf. (%)
€1.60
06.12.21
06.12.21
€2.80
06.12.22
06.12.22
-1.25%
07.12.22
07.12.22
Could be worthwhile Investment >10% per year
Radius Health Inc.
Start price
Target price
Perf. (%)
€13.05
05.12.21
05.12.21
-
05.12.22
05.12.22
-48.66%
11.12.21
11.12.21
Risky Investment
MacroGenics Inc.
Start price
Target price
Perf. (%)
€14.88
05.12.21
05.12.21
-
05.12.22
05.12.22
0.47%
12.12.21
12.12.21
Risky Investment
Novavax Inc.
Start price
Target price
Perf. (%)
€147.98
05.12.21
05.12.21
-
05.12.22
05.12.22
-23.17%
07.01.22
07.01.22
Could be worthwhile Investment >10% per year
Fate Therapeutics Inc.
Start price
Target price
Perf. (%)
€42.42
03.12.21
03.12.21
-
03.12.22
03.12.22
7.50%
11.12.21
11.12.21
Risky Investment
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€4.62
03.12.21
03.12.21
-
03.12.22
03.12.22
0.84%
11.12.21
11.12.21
Could be worthwhile Investment >10% per year
Adaptimmune Therapeutics PLC ADR
Start price
Target price
Perf. (%)
€3.28
02.12.21
02.12.21
-
02.12.22
02.12.22
-0.61%
11.12.21
11.12.21
Risky Investment
Lannett Co. Inc.
Start price
Target price
Perf. (%)
€5.88
01.12.21
01.12.21
-
01.12.22
01.12.22
-61.58%
02.12.22
02.12.22
Could be worthwhile Investment >10% per year
Future proof or reliable business model
Revenue growth > 30% per year expected
High Investments for future growth
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€4.85
01.12.21
01.12.21
-
01.12.22
01.12.22
-53.67%
02.12.22
02.12.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model
Myovant Sciences Ltd
Start price
Target price
Perf. (%)
€14.52
01.12.21
01.12.21
-
01.12.22
01.12.22
-11.23%
11.12.21
11.12.21
Could be very worthwhile Investment >20% year